The IBD SmartSelect Composite Rating for Mirum Pharmaceuticals rose from 91 to 96 Friday.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The best stocks tend to have a 95 or better grade as they start a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Mirum Pharmaceuticals has now climbed above a proper buy zone after breaking out from a 51.93 entry in a cup with handle.
One weak spot is the company's 53 EPS Rating, which tracks quarterly and annual earnings-per-share growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors over the last 13 weeks.
The company reported 0% earnings-per-share growth for Q2. Sales growth climbed 64%, up from 61% in the prior report. The company has now posted rising growth in each of the last two reports.
Mirum Pharmaceuticals holds the No. 8 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Rigel Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
